Ilex/Millennium Campath
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Joint venture responds August 21 to FDA's June 23 complete response letter for the lymphocytic leukemia treatment. The response includes additional analysis and follow-up data. The alemtuzumab BLA, submitted in December 1999, may be reviewed by FDA's Oncologic Drugs Advisory Committee at its December meetin